BN Business News
Add your company to Business Communicator →

Zdrowie i gospodarka · 27/12/1999

Withdrawal of Guidance Document on Selegiline Hydrochloride Tablets

The Food and Drug Administration (FDA) is withdrawing a guidance for industry entitled ``Selegiline Hydrochloride Tablets: In Vivo Bioequivalence and In Vitro Dissolution Testing.'' This guidance, which was issued in December 1995, is being withdrawn because it does not represent current agency thinking on in vivo bioequivalence (BE) and in vitro testing for selegiline hydrochloride.

Source: Federal Register — Food and Drug AdministrationOpen original release →